Show simple item record

dc.contributor.authorSmith, HGen_US
dc.contributor.authorJamal, Ken_US
dc.contributor.authorDayal, JHen_US
dc.contributor.authorTenev, Ten_US
dc.contributor.authorKyula-Currie, Jen_US
dc.contributor.authorGuppy, Nen_US
dc.contributor.authorGazinska, Pen_US
dc.contributor.authorRoulstone, Ven_US
dc.contributor.authorLiccardi, Gen_US
dc.contributor.authorDavies, Een_US
dc.contributor.authorRoxanis, Ien_US
dc.contributor.authorMelcher, AAen_US
dc.contributor.authorHayes, AJen_US
dc.contributor.authorInman, GJen_US
dc.contributor.authorHarrington, KJen_US
dc.contributor.authorMeier, Pen_US
dc.date.accessioned2020-05-21T12:07:39Z
dc.date.issued2020-06en_US
dc.identifier.citationEMBO molecular medicine, 2020, 12 (6), pp. e10979 - ?en_US
dc.identifier.issn1757-4676en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3622
dc.identifier.eissn1757-4684en_US
dc.identifier.doi10.15252/emmm.201910979en_US
dc.description.abstractDrugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti-tumour immunity but not every form of death can elicit an immune response. Moreover, resistance to apoptosis is a major problem in cancer treatment and disease control. While the term "immunogenic cell death" is not fully defined, activation of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) can induce a type of death that mobilises the immune system against cancer. However, no clinical treatment protocols have yet been established that would harness the immunogenic potential of RIPK1. Here, we report the first pre-clinical application of an in vivo treatment protocol for soft-tissue sarcoma that directly engages RIPK1-mediated immunogenic cell death. We find that RIPK1-mediated cell death significantly improves local disease control, increases activation of CD8+ T cells as well as NK cells, and enhances the survival benefit of immune checkpoint blockade. Our findings warrant a clinical trial to assess the survival benefit of RIPK1-induced cell death in patients with advanced disease at limb extremities.en_US
dc.formatPrint-Electronicen_US
dc.format.extente10979 - ?en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleRIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.en_US
dc.typeJournal Article
dcterms.dateAccepted2020-04-20en_US
rioxxterms.versionofrecord10.15252/emmm.201910979en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2020-06en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEMBO molecular medicineen_US
pubs.issue6en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Cell Death and Immunity
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Sarcoma and Melanoma Surgery
pubs.publication-statusPublisheden_US
pubs.volume12en_US
pubs.embargo.termsNot knownen_US
icr.researchteamCell Death and Immunityen_US
icr.researchteamSarcoma and Melanoma Surgeryen_US
dc.contributor.icrauthorHayes, Andrewen_US
dc.contributor.icrauthorMeier, Pascalen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/